{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:47:26Z","timestamp":1794541646046,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-10-IBHU-0001"],"award-info":[{"award-number":["ANR-10-IBHU-0001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Institut de Recherche en Sant\u00e9 Publique"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11136-021-02794-5","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T13:02:49Z","timestamp":1614690169000},"page":"2021-2032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Health state utility and quality of life measures in patients with chronic myeloid leukemia in France"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0213-0736","authenticated-orcid":false,"given":"Foulon","family":"S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cony-Makhoul","family":"P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guerci-Bresler","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daban","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapso","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tubert-Bitter","family":"P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonastre","family":"J","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"issue":"9976","key":"2794_CR1","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley, J. F. (2015). Chronic myeloid leukaemia. Lancet (London, England), 385(9976), 1447\u20131459. https:\/\/doi.org\/10.1016\/S0140-6736(13)62120-0.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2794_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.respe.2015.12.017","volume":"64","author":"S Le Guyader-Peyrou","year":"2016","unstructured":"Le Guyader-Peyrou, S., Belot, A., Maynadi\u00e9, M., Binder-Foucard, F., Remontet, L., Troussard, X., et al. (2016). Cancer incidence in France over the 1980\u20132012 period: Hematological malignancies. Revue D\u2019epidemiologie Et De Sante Publique, 64(2), 103\u2013112. https:\/\/doi.org\/10.1016\/j.respe.2015.12.017.","journal-title":"Revue D\u2019epidemiologie Et De Sante Publique"},{"issue":"Suppl 2","key":"2794_CR3","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund, M., Sandin, F., & Simonsson, B. (2015). Epidemiology of chronic myeloid leukaemia: An update. Annals of Hematology, 94(Suppl 2), S241-247. https:\/\/doi.org\/10.1007\/s00277-015-2314-2.","journal-title":"Annals of Hematology"},{"issue":"6","key":"2794_CR4","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1002\/cam4.2200","volume":"8","author":"S Foulon","year":"2019","unstructured":"Foulon, S., Cony-Makhoul, P., Guerci-Bresler, A., Delord, M., Solary, E., Monnereau, A., et al. (2019). Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study. Cancer Medicine, 8(6), 3296\u20133304. https:\/\/doi.org\/10.1002\/cam4.2200.","journal-title":"Cancer Medicine"},{"issue":"24","key":"2794_CR5","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower, H., Bj\u00f6rkholm, M., Dickman, P. W., H\u00f6glund, M., Lambert, P. C., & Andersson, T.M.-L. (2016). Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34(24), 2851\u20132857. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"2794_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","volume":"2017","author":"F-X Mahon","year":"2017","unstructured":"Mahon, F.-X. (2017). Treatment-free remission in CML: Who, how, and why? Hematology American Society of Hematology. Education Program, 2017(1), 102\u2013109. https:\/\/doi.org\/10.1182\/asheducation-2017.1.102.","journal-title":"Hematology American Society of Hematology. Education Program"},{"issue":"14","key":"2794_CR7","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1002\/cncr.31411","volume":"124","author":"D Rea","year":"2018","unstructured":"Rea, D., Ame, S., Berger, M., Cayuela, J.-M., Charbonnier, A., Coiteux, V., et al. (2018). Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer, 124(14), 2956\u20132963. https:\/\/doi.org\/10.1002\/cncr.31411.","journal-title":"Cancer"},{"issue":"1","key":"2794_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","volume":"2016","author":"F Efficace","year":"2016","unstructured":"Efficace, F., & Cannella, L. (2016). The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology American Society of Hematology Education Program, 2016(1), 170\u2013179. https:\/\/doi.org\/10.1182\/asheducation-2016.1.170.","journal-title":"Hematology American Society of Hematology Education Program"},{"issue":"11","key":"2794_CR9","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn, E. A., Glendenning, G. A., Sorensen, M. V., Hudgens, S. A., Druker, B. J., Guilhot, F., et al. (2003). Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21(11), 2138\u20132146. https:\/\/doi.org\/10.1200\/JCO.2003.12.154.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"2794_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","volume":"36","author":"PC Trask","year":"2012","unstructured":"Trask, P. C., Cella, D., Besson, N., Kelly, V., Masszi, T., & Kim, D.-W. (2012). Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leukemia Research, 36(4), 438\u2013442. https:\/\/doi.org\/10.1016\/j.leukres.2011.10.011.","journal-title":"Leukemia Research"},{"issue":"8","key":"2794_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1185\/03007995.2016.1174108","volume":"32","author":"J Whiteley","year":"2016","unstructured":"Whiteley, J., Reisman, A., Shapiro, M., Cortes, J., & Cella, D. (2016). Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Current Medical Research and Opinion, 32(8), 1325\u20131334. https:\/\/doi.org\/10.1185\/03007995.2016.1174108.","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"2794_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/10428194.2015.1049166","volume":"57","author":"JS Park","year":"2016","unstructured":"Park, J. S., Lee, S.-E., Jeong, S. H., Jang, E.-J., Choi, M.-Y., Kim, H.-J., et al. (2016). Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leukemia & Lymphoma, 57(2), 341\u2013347. https:\/\/doi.org\/10.3109\/10428194.2015.1049166.","journal-title":"Leukemia & Lymphoma"},{"issue":"10","key":"2794_CR13","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.31323","volume":"124","author":"F Efficace","year":"2018","unstructured":"Efficace, F., Castagnetti, F., Martino, B., Breccia, M., D\u2019Adda, M., Angelucci, E., et al. (2018). Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer, 124(10), 2228\u20132237. https:\/\/doi.org\/10.1002\/cncr.31323.","journal-title":"Cancer"},{"issue":"2","key":"2794_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41375-019-0563-0","volume":"34","author":"F Efficace","year":"2020","unstructured":"Efficace, F., Stagno, F., Iurlo, A., Breccia, M., Cottone, F., Bonifacio, M., et al. (2020). Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia, 34(2), 488\u2013498. https:\/\/doi.org\/10.1038\/s41375-019-0563-0.","journal-title":"Leukemia"},{"issue":"17","key":"2794_CR15","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., et al. (2011). Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood, 118(17), 4554\u20134560. https:\/\/doi.org\/10.1182\/blood-2011-04-347575.","journal-title":"Blood"},{"issue":"4","key":"2794_CR16","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","volume":"21","author":"KM Phillips","year":"2013","unstructured":"Phillips, K. M., Pinilla-Ibarz, J., Sotomayor, E., Lee, M. R., Jim, H. S. L., Small, B. J., et al. (2013). Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 21(4), 1097\u20131103. https:\/\/doi.org\/10.1007\/s00520-012-1630-5.","journal-title":"Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"11","key":"2794_CR17","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1002\/cncr.20694","volume":"101","author":"SD Reed","year":"2004","unstructured":"Reed, S. D., Anstrom, K. J., Ludmer, J. A., Glendenning, G. A., & Schulman, K. A. (2004). Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 101(11), 2574\u20132583. https:\/\/doi.org\/10.1002\/cncr.20694.","journal-title":"Cancer"},{"issue":"23","key":"2794_CR18","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood.V126.23.4024.4024","volume":"126","author":"AM Labeit","year":"2015","unstructured":"Labeit, A. M., Copland, M., Cork, L. M., Hedgley, C., Foroni, L., Osborne, W. L., et al. (2015). Assessment of quality of life in the NCRI spirit 2 study comparing imatinib with dasatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia. Blood, 126(23), 4024.","journal-title":"Blood"},{"issue":"1","key":"2794_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","volume":"13","author":"SM Szabo","year":"2010","unstructured":"Szabo, S. M., Levy, A. R., Davis, C., Holyoake, T. L., & Cortes, J. (2010). A multinational study of health state preference values associated with chronic myelogenous leukemia. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 13(1), 103\u2013111. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00573.x.","journal-title":"Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"issue":"5","key":"2794_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3109\/10428194.2011.631155","volume":"53","author":"JF Guest","year":"2012","unstructured":"Guest, J. F., Naik, N., Sladkevicius, E., Coombs, J., & Gray, E. J. (2012). Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leukemia & Lymphoma, 53(5), 928\u2013933. https:\/\/doi.org\/10.3109\/10428194.2011.631155.","journal-title":"Leukemia & Lymphoma"},{"issue":"8","key":"2794_CR21","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3109\/10428194.2013.854886","volume":"55","author":"JF Guest","year":"2014","unstructured":"Guest, J. F., Gray, E. J., Szczudlo, T., & Magestro, M. (2014). Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom. Leukemia & Lymphoma, 55(8), 1870\u20131875. https:\/\/doi.org\/10.3109\/10428194.2013.854886.","journal-title":"Leukemia & Lymphoma"},{"issue":"3","key":"2794_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. (1990). EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands), 16(3), 199\u2013208.","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"issue":"5","key":"2794_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365\u2013376.","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"2794_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace, F., Baccarani, M., Breccia, M., Saussele, S., Abel, G., Caocci, G., et al. (2014). International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 23(3), 825\u2013836. https:\/\/doi.org\/10.1007\/s11136-013-0523-5.","journal-title":"Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation"},{"issue":"1","key":"2794_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10198-011-0351-x","volume":"14","author":"J Chevalier","year":"2013","unstructured":"Chevalier, J., & de Pouvourville, G. (2013). Valuing EQ-5D using time trade-off in France. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care, 14(1), 57\u201366. https:\/\/doi.org\/10.1007\/s10198-011-0351-x.","journal-title":"The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care"},{"key":"2794_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1838509","author":"F Efficace","year":"2020","unstructured":"Efficace, F., Iurlo, A., Patriarca, A., Stagno, F., Bee, P.-C., Ector, G., et al. (2020). Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia & Lymphoma. https:\/\/doi.org\/10.1080\/10428194.2020.1838509.","journal-title":"Leukemia & Lymphoma"},{"key":"2794_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-reported population health: An international perspective based on EQ-5D","author":"A Szende","year":"2014","unstructured":"Szende, A., Janssen, B., & Cabases, J. (2014). Self-reported population health: An international perspective based on EQ-5D. Netherlands: Springer."},{"key":"2794_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2018.11.023","volume":"107","author":"G Liegl","year":"2019","unstructured":"Liegl, G., Petersen, M. A., Groenvold, M., Aaronson, N. K., Costantini, A., Fayers, P. M., et al. (2019). Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core. European Journal of Cancer (Oxford, England: 1990), 107, 133\u2013141. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.023.","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"issue":"1","key":"2794_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(1), 89\u201396. https:\/\/doi.org\/10.1200\/JCO.2010.28.0107.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"2","key":"2794_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/14737167.2014.894462","volume":"14","author":"S Coretti","year":"2014","unstructured":"Coretti, S., Ruggeri, M., & McNamee, P. (2014). The minimum clinically important difference for EQ-5D index: A critical review. Expert Review of Pharmacoeconomics & Outcomes Research, 14(2), 221\u2013233. https:\/\/doi.org\/10.1586\/14737167.2014.894462.","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"key":"2794_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes, 5, 70. https:\/\/doi.org\/10.1186\/1477-7525-5-70.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"4","key":"2794_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","volume":"87","author":"AK Kvam","year":"2011","unstructured":"Kvam, A. K., Fayers, P. M., & Wisloff, F. (2011). Responsiveness and minimal important score differences in quality-of-life questionnaires: A comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. European Journal of Haematology, 87(4), 330\u2013337. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01665.x.","journal-title":"European Journal of Haematology"},{"issue":"4","key":"2794_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.clinthera.2014.02.008","volume":"36","author":"W Kulpeng","year":"2014","unstructured":"Kulpeng, W., Sompitak, S., Jootar, S., Chansung, K., & Teerawattananon, Y. (2014). Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clinical Therapeutics, 36(4), 534\u2013543. https:\/\/doi.org\/10.1016\/j.clinthera.2014.02.008.","journal-title":"Clinical Therapeutics"},{"key":"2794_CR34","doi-asserted-by":"publisher","first-page":"b2688","DOI":"10.1136\/bmj.b2688","volume":"339","author":"D Arnold","year":"2009","unstructured":"Arnold, D., Girling, A., Stevens, A., & Lilford, R. (2009). Comparison of direct and indirect methods of estimating health state utilities for resource allocation: Review and empirical analysis. BMJ (Clinical Research Esd.), 339, b2688. https:\/\/doi.org\/10.1136\/bmj.b2688.","journal-title":"BMJ (Clinical Research Esd.)"},{"issue":"2","key":"2794_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","volume":"15","author":"NJ Devlin","year":"2017","unstructured":"Devlin, N. J., & Brooks, R. (2017). EQ-5D and the EuroQol Group: Past, Present and Future. Applied Health Economics and Health Policy, 15(2), 127\u2013137. https:\/\/doi.org\/10.1007\/s40258-017-0310-5.","journal-title":"Applied Health Economics and Health Policy"},{"issue":"11","key":"2794_CR36","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1002\/cam4.1808","volume":"7","author":"A Zulbaran-Rojas","year":"2018","unstructured":"Zulbaran-Rojas, A., Lin, H.-K., Shi, Q., Williams, L. A., George, B., Garcia-Manero, G., et al. (2018). A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Medicine, 7(11), 5457\u20135469. https:\/\/doi.org\/10.1002\/cam4.1808.","journal-title":"Cancer Medicine"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-02794-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-021-02794-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-02794-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T11:42:00Z","timestamp":1624621320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-021-02794-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["2794"],"URL":"https:\/\/doi.org\/10.1007\/s11136-021-02794-5","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"8 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest\/competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the French ethics committee Comit\u00e9 de Protection des Personnes Ile de France 7.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients were informed of the research purpose of the study and consented to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. Only aggregated data are provided in the article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}